{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:02Z","timestamp":1791465062990,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.josat.2023.209139","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T20:11:13Z","timestamp":1692821473000},"page":"209139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset"],"prefix":"10.1016","volume":"154","author":[{"given":"Shirley","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Tharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.209139_bb0005","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2021"},{"key":"10.1016\/j.josat.2023.209139_bb0010","series-title":"Trends in the Use of Methadone, Buprenorphine, and Extended-release Naltrexone at Substance Abuse Treatment Facilities: 2003\u20132015 (Update). The CBHSQ Report: August 22, 2017","author":"Alderks","year":"2017"},{"issue":"4","key":"10.1016\/j.josat.2023.209139_bb0015","article-title":"Identification and estimation of local average treatment effects","volume":"62","author":"Angrist","year":"1994","journal-title":"Econometrica"},{"issue":"10","key":"10.1016\/j.josat.2023.209139_bb0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamapsychiatry.2021.1969","article-title":"Contingency management for patients receiving medication for opioid use disorder: A systematic review and meta-analysis","volume":"78","author":"Bol\u00edvar","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.josat.2023.209139_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.josat.2023.209139_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugpo.2019.07.006","article-title":"Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States","volume":"73","author":"Davis","year":"2019","journal-title":"The International Journal on Drug Policy"},{"issue":"4","key":"10.1016\/j.josat.2023.209139_bb0035","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1097\/ADM.0000000000000679","article-title":"Opioid policy changes during the COVID-19 pandemic - and beyond","volume":"14","author":"Davis","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.209139_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108784","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"10.1016\/j.josat.2023.209139_bb0045","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"10","key":"10.1016\/j.josat.2023.209139_bb0050","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Medical Care"},{"issue":"2","key":"10.1016\/j.josat.2023.209139_bb0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11524-022-00610-0","article-title":"Impact of the COVID-19 pandemic on opioid overdose deaths: A spatiotemporal analysis","volume":"99","author":"Ghose","year":"2022","journal-title":"Journal of Urban Health: Bulletin of the New York Academy of Medicine"},{"key":"10.1016\/j.josat.2023.209139_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108651","article-title":"Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective","volume":"221","author":"Hall","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.josat.2023.209139_bb0065","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: A primary care cohort study in the United Kingdom","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2023.209139_bb0070","series-title":"Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives","first-page":"73","article-title":"The propensity score with continuous treatments","volume":"226164","author":"Hirano","year":"2004"},{"issue":"18","key":"10.1016\/j.josat.2023.209139_bb0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.josat.2023.209139_bb0085","author":"Kaiser Family Foundation"},{"key":"10.1016\/j.josat.2023.209139_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jsat.2019.05.015","article-title":"A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective","volume":"104","author":"Kinsky","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"15","key":"10.1016\/j.josat.2023.209139_bb0095","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"6","key":"10.1016\/j.josat.2023.209139_bb0100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jamapsychiatry.2020.4148","article-title":"The hidden epidemic of opioid overdoses during the coronavirus disease 2019 pandemic","volume":"78","author":"Kosten","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2023.209139_bb5005","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"The International journal on drug policy"},{"key":"10.1016\/j.josat.2023.209139_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108367","article-title":"The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review","volume":"127","author":"Kumar","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.josat.2023.209139_bb0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1016\/j.josat.2023.209139_bb0115","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1111\/ajt.14555","article-title":"Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas-United States","volume":"17","author":"Mack","year":"2017","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.josat.2023.209139_bb0120","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1016\/j.josat.2023.209139_bb5010","doi-asserted-by":"crossref","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA network open"},{"key":"10.1016\/j.josat.2023.209139_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108382","article-title":"The cost of opioid use disorder and the value of aversion","volume":"217","author":"Murphy","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.josat.2023.209139_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.josat.2023.209139_bb0135","article-title":"Demographic and geospatial analysis of buprenorphine and methadone prescription rates","volume":"14","author":"Peterman","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.josat.2023.209139_bb0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","article-title":"Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets","volume":"14","author":"Prieto-Merino","year":"2021","journal-title":"Journal of Pharmaceutical Policy and Practice"},{"key":"10.1016\/j.josat.2023.209139_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"6","key":"10.1016\/j.josat.2023.209139_bb0155","first-page":"e172","article-title":"Heterogeneity of nonadherent buprenorphine patients: Subgroup characteristics and outcomes","volume":"23","author":"Ruetsch","year":"2017","journal-title":"The American Journal of Managed Care"},{"issue":"1_suppl","key":"10.1016\/j.josat.2023.209139_bb0160","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1177\/0033354918793627","article-title":"A public health strategy for the opioid crisis","volume":"133","author":"Saloner","year":"2018","journal-title":"Public Health Reports"},{"issue":"5","key":"10.1016\/j.josat.2023.209139_bb0165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.josat.2023.209139_bb0170","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"issue":"1","key":"10.1016\/j.josat.2023.209139_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nature Reviews. Disease Primers"},{"issue":"2","key":"10.1016\/j.josat.2023.209139_bb0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"issue":"4","key":"10.1016\/j.josat.2023.209139_bb0185","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","article-title":"Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients","volume":"46","author":"Tkacz","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209139_bb5000","doi-asserted-by":"crossref","first-page":"107345","DOI":"10.1016\/j.ypmed.2022.107345","article-title":"Total cost of care associated with opioid use disorder treatment","volume":"166","author":"Toseef","year":"2023","journal-title":"Preventive medicine"},{"key":"10.1016\/j.josat.2023.209139_bb0190","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/CEOR.S334274","article-title":"Comparison of healthcare resource utilization between patients who engaged or did not engage with a prescription digital therapeutic for opioid use disorder","volume":"13","author":"Velez","year":"2021","journal-title":"ClinicoEconomics and Outcomes Research"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294987592300190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294987592300190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:50:25Z","timestamp":1757433025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294987592300190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"alternative-id":["S294987592300190X"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209139","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209139"}}